Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting.

Read more at globenewswire.com